Efficacy

Choose TRILEPTAL when the goal is control in adult patients TRILEPTAL efficacy as monotherapy In newly diagnosed adult patients (48-week study) In newly diagnosed adult patients (3-year open-label extension) In adult patients converted from other antiepileptic drugs In adult patients who remained on TRILEPTAL therapy (2-year open-label extension)

Adult Efficacy Pediatric Efficacy First-line Use TRILEPTAL vs CBZ

TRILEPTAL efficacy as adjunctive therapy
		For additional partial seizure control when added to one or more antiepileptic drugs in adult patients

Choose TRILEPTAL when the goal is control in pediatric patients

TRILEPTAL efficacy as monotherapy
		In newly diagnosed pediatric patients

TRILEPTAL efficacy as adjunctive therapy
		For additional partial seizure control in pediatric patients (aged 2 to < 4 years)
		For additional partial seizure control in pediatric patients (aged 4 to 17 years)

Learn more about monotherapy
See how monotherapy is a realistic goal for most patients and review data about TRILEPTAL efficacy in monotherapy

TRILEPTAL versus Carbamazepine (CBZ)

Explore the clinical benefits of TRILEPTAL versus CBZ in monotherapy and adjunctive therapy and learn about the differences in chemical structure between the two compounds